A Rationally Designed Fully Human EGFRvIII:CD3-targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-Derived Intracerebral Malignant Glioma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-17-0126
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry Approach

English

PS2 - 172 Preclinical Validation of a Novel CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody to Target Patient-Derived Glioblastoma Cells

Canadian Journal of Neurological Sciences
MedicineNeurology
2016English

Cytotoxicity of Cytokine‑induced Killer Cells Targeted by a Bispecific Antibody to Gastric Cancer Cells

Oncology Letters
Cancer ResearchOncology
2013English

A Rationally Designed Agonist Antibody Fragment That Functionally Mimics Thrombopoietin

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2006English

TGF- Mediates Homing of Bone Marrow-Derived Human Mesenchymal Stem Cells to Glioma Stem Cells

Cancer Research
Cancer ResearchOncology
2013English

182. Genetically Engineered Malignant Glioma-Specific T Cells Resistant to Glucocorticoids

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2010English

Human Vγ9Vδ2-T Cells Synergize CD4+ T Follicular Helper Cells to Produce Influenza Virus-Specific Antibody

Frontiers in Immunology
AllergyImmunology
2018English

Rationally Designed Tularemia Vaccines

Expert Review of Vaccines
Molecular MedicineDrug DiscoveryImmunologyPharmacology
2009English

MicroRNA-93 Promotes the Malignant Phenotypes of Human Glioma Cells and Induces Their Chemoresistance to Temozolomide

Biology Open
BiochemistryAgriculturalGeneticsMolecular BiologyBiological Sciences
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy